Group 1 - Cloudbreak Pharma Inc. (referred to as "Cloudbreak") plans to issue 60.582 million H-shares from June 24 to June 27, with an expected listing date on the Hong Kong Stock Exchange on July 3, 2025 [1][3] - The offering price is set at HKD 10.10 per share, aiming to raise approximately HKD 612 million, with a net fundraising amount of about HKD 522 million [3] - Key investors include Fuzhi Holdings Limited and The Reynold Lemkins Group (Asia) Limited, which collectively subscribed for approximately USD 28.8 million worth of shares [3] Group 2 - Cloudbreak is a clinical-stage ophthalmic biotechnology company focused on developing various therapies, with two core products: CBT-001 for treating pterygium and CBT-009 for juvenile myopia [5] - The company has other candidate drugs in early development stages, including two clinical-stage candidates and four preclinical-stage candidates [5] - Revenue projections for Cloudbreak are approximately zero for 2022 and 2023, with an expected revenue of USD 10 million in 2024; net losses are projected at USD 66.838 million, USD 129 million, and USD 99.13 million for the respective years [5] Group 3 - The funds raised from the IPO will be allocated to the continued clinical development of core product CBT-001, regulatory filing, and approval-related research, as well as costs associated with the development of CBT-009 [5]
拨康视云开启招股，将于7月3日在港交所上市，募资约6亿港元